Holen Sie sich die Stockscreener-App
0.2895
0.70%
0.002
Handel nachbörslich:
.29
0.0005
+0.17%
Schlusskurs vom Vortag:
$0.2875
Offen:
$0.2876
24-Stunden-Volumen:
661.74K
Relative Volume:
0.26
Marktkapitalisierung:
$13.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-0.0891
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
-7.03%
1M Leistung:
+11.69%
6M Leistung:
-86.84%
1J Leistung:
-92.65%
1-Tages-Spanne:
$0.2741
$0.2906
1-Wochen-Bereich:
$0.2741
$0.32
52-Wochen-Spanne:
$0.224
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2895 | 13.34M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
CLRB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Prepare Yourself for Liftoff: Cellectar Biosciences Inc (CLRB) - SETE News
StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
SEC Form 424B3 filed by Cellectar Biosciences Inc. - Quantisnow
A look into Cellectar Biosciences Inc (CLRB)’s deeper side - SETE News
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Cellectar Biosciences, Inc. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq
Cellectar Biosciences Showcases Cancer Treatment Pipeline at Major Healthcare Conference - StockTitan
Examining Cellectar Biosciences Inc (CLRB) stock is warranted - US Post News
Cellectar faces Nasdaq delisting over share price rule - MSN
Market Momentum Report: Cellectar Biosciences Inc (CLRB)’s Positive Close at 0.26 - The Dwinnex
Rosalind Advisors, Inc. Increases Stake in Cellectar Biosciences Inc - GuruFocus.com
Cellectar faces Nasdaq delisting over share price rule By Investing.com - Investing.com Australia
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire
Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar stock plunges 50% post-market on restructuring news - MSN
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold
Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register
Neuroblastoma Therapeutic Market: Analyzing the Impact of High - openPR
Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN
Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World
Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World
Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha
CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan
Cellectar refocuses on solid tumor radiotherapies - Investing.com
Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire
Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan
Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):